This is
NOVAICOS Srls works on innovative solutions against bone erosion, with particular focus on osteoporosis, the aim is to deveope new compounds active in inhibiting bone resorption.
The problem
Major osteoporotic fractures are a serious health problem in the increasingly elder population. Elderly suffering with femoral fractures will die within a year (15-25%) or become dependent (50%). Fractures impair patients’ quality of life, increase mortality and social costs. In developed countries, the lifetime risk for major osteoporotic fractures is 30% to 40%, very close to that for coronary heart disease. The number of post-menopausal women living with osteoporosis was predicted to increase of about 16.5% within 2020, this increase will be associated with an increase in the number of fractures between 16 and 18%.
The innovative solution
Novaicos new drug (ICOS-Fc) provide a new approach for the treatment of osteoporosis that will reduce fracture risk, ameliorate treatment outcomes with reduced side effects. ICOS-Fc has a selective and fully reversible effect on bone resorption. (Patent pending Italian No.102015000018209 international PCT/IB2016/052903).
The landscape
Main competitors are old molecules as bisphosphonates (Fosamax®, Actonel®, and others) 1-34 teriparatide (Forsteo®), SERMS (Conbriza®, Evista®) and Denosumab (Prolia®), these molecules have major contra-indications and several adverse events as bleeding, uveitis, osteonecrosis of the jaw and atypical fractures. The market for anti-osteoporotic drugs has been evaluated in 8,8 B $ in 2015, with a 3.8% increase/yrs.
Development
Target
Development of new molecules active on bone resorption in different osteolytic diseases as osteoporosis and bone metastases. The first patented molecule is ICOS-Fc. ICOS-Fc is active in osteoporosis and osteopenia with possible development in the fields of autoimmunity and oncology.
Research for investors and industrial partners for the development of the research and clinical phase studies.
